# Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC

> **NCT07200154** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Limited-stage Small-cell Lung Cancer
- Concurrent Chemoradiation Therapy

## Interventions

- **DRUG:** Adebrelimab with concurrent chemoradiotherapy

## Key facts

- **NCT ID:** NCT07200154
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200154, "Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07200154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*